Nicox S.A.
NICXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.17M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $29.17 Million |
|---|---|
| Enterprise Value | $26.04 Million |
| Earnings per Share | $-0.03 |
| Beta | 0.52 |
| Outstanding Shares | 69,899,000 |
Return
| Return on Equity | -561.14% |
|---|---|
| Return on Assets | -283.16% |
| Return on Invested Capital | -314.80% |
Valuation & Multiples
| P/E Ratio | -6.39 |
|---|---|
| PEG | 4.28 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.06 |
| Enterprise Value to EBIT | -1.31 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Next Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Nicox S.A.
10 employees
CEO: Gavin Spencer
Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric o...